drugset / Trial / NCT05075538
COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
NaSingle-groupOpen-labelPrevention
Summary
This trial aims to measure the humoral and adaptive immune response in patients with cancer diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in preventing COVID-19.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2024-01-08
- Completion
- 2024-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BNT162b2 | Messenger RNA (mRNA) | — | — |
| Subject | Comirnaty Omicron XBB1.5 | Vaccine | — | — |
| Subject | Comirnaty Original/Omicron BA.1 | Unknown | — | — |
| Subject | Comirnaty Original/Omicron BA.4-5 | Unknown | — | — |
| Subject | Elasomeran | Messenger RNA (mRNA) | — | — |
| Subject | Spikevax Omicron XBB.1.5 | Unknown | — | — |
| Subject | Spikevax bivalent Original/Omicron BA.1 | Unknown | — | — |
| Subject | Spikevax bivalent Original/Omicron BA.4-5 | Unknown | — | — |